Author name: Leonardo Arias

Novo has “gone shopping” to fill pipeline gaps, with a focus on obesity and diabetes, plus an expansion in blood and endocrine disorders, liver diseases and cardiovascular conditions.

The company will generate population-scale molecular data to inform development of diagnostics, therapies and other healthcare products.

Aside from its manufacturing and distribution footprint, ITM Isotope Technologies Munich will give Telix Pharmaceuticals the late-stage ITM-11, being developed for gastroenteropancreatic neuroendocrine tumors. The asset was rejected by the FDA last month for manufacturing concerns.

Investors and analysts have been hounding Novo to beef up its pipeline and advance new molecules as a majority of the company’s sales stem from its semaglutide franchise.

Healthcare organizations are rich in clinical data, but much of it is fragmented and unstructured. How can AI help transform it into structured, research-ready variables?

The true cost of payment operations sits in four budgets. What happens when you add them up?

Disconnected care can be a major – and often overlooked – driver of unnecessary healthcare costs.

La teoría de la relatividad general de Albert Einstein nos enseñó que nada, ni siquiera la luz, puede escapar del horizonte de sucesos de un agujero negro. Sin embargo, las ecuaciones matemáticas que describen estos monstruos cósmicos esconden un reverso especular: …

Cuando un bosque tropical se convierte en pastizal, un humedal se seca o un arrecife de coral pierde su vitalidad, la ecología de la restauración interviene con una meta ambiciosa: devolver a la naturaleza su funcionalidad original. Sin embargo, antes de plantar el primer árbol …

A mediados del siglo XX, la biología molecular operaba bajo un dogma en apariencia inquebrantable: el ADN contenía las instrucciones genéticas, las proteínas ejecutaban las tareas metabólicas y el ARN actuaba únicamente como un mero mensajero intermedio. Sin …